|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents?显示文摘Recurrence of hepatitis C virus(HCV)infection following liver transplantation(LT)is almost universal and can accelerate graft cirrhosis in up to 30%of patients.The development of effective strategies to treat or prevent HCV recurrence after LT remains a major challenge,considering the shortage of donor organs and the accelerated progression of HCV in LT recipients.Standard antiviral therapy with pegylated-interferon plus ribavirin is the current treatment of choice for HCV LT recipients,even though the combination is not as effective as it is in immunocompetent patients.A sustained virological response in the setting of LT improves patient and graft survival,but this is only achieved in 30%-45%of patients and the treatment is poorly tolerated.To improve the efficacy of pre-and post-transplant antiviral therapy,a new class of potent direct-acting antiviral agents (DAAs)has been developed.The aim of this review is to summarize the use of DAAs in LT HCV patients.PubMed,Cochrane Library,MEDLINE,EMBASE,Web of Science and clinical trial databases were searched for this purpose.To date,only three clinical studies on the topic have been published and most of the available data are in abstract form.Although a moderately successful early virological response has been reported,DAA treatment regimens were associated with severe toxicity mitigating their potential usefulness.Moreover,the ongoing nature of data,the lack of randomized studies,the small number of enrolled patients and the heterogeneity of these studies make the results largely anecdotal and questionable.In conclusion,large welldesigned clinical studies on DAAs in HCV LT patients are required before these drugs can be recommended after transplantation. | Marco Dall’Agata Annagiulia Gramenzi Maurizio Biselli Mauro Bernardi | 2014 | World Journal of Gastroenterology2014，20，28： | 4 |
| 2 | Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival显示文摘 | Valentina Santi Franco Trevisani Annagiulia Gramenzi Alice Grignaschi Federica Mirici-Cappa Paolo Del Poggio Maria Anna Di Nolfo Luisa Benvegnù Fabio Farinati Marco Zoli Edoardo Giovanni Giannini Franco Borzio Eugenio Caturelli Maria Chiaramonte Mauro Ber | 2010 | Journal of Hepatology2010，，2： | 1 |
| 3 | Ketoprofen,peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C:A phaseⅡ study显示文摘AIM:To evaluate the safety of adding ketoprofen to pegylated-interferon(PEG-IFN)with or without ribavirin and the effect on viral kinetics,STAT1 activity and expression of 2'-5'-oligoadenylate synthetase (2'-5'OAS)in genotype 1 chronic hepatitis C in a phaseⅡstudy. METHODS:Forty-five patients were studied:fifteen were randomized to PEG-IFN plus ribavirin(PR),16 to PEGIFN plus ketoprofen and 14 to PR and ketoprofen.Themolecular study of IFN-dependent signal transduction was conducted in 9 patients from each group. RESULTS:The combination of ketoprofen and PEG- IFN with or without ribavirin was safe and well tolerated.An early activation of STAT1 was observed in ke-toprofen-treated patients,but this activation was less sustained over time.Conversely,ketoprofen plus PEG- IFN and ribavirin induced an early and sustained increase of 2'-5'OAS transcription starting 24 h after the first dose until the 36th wk.These data are consistent with the clinical results,showing a better sustained virological response and a lower relapse rate in patients receiving ketoprofen plus PEG-IFN and ribavirin. CONCLUSION:The addition of ketoprofen to the standard therapy of chronic hepatitis C should be explored in larger randomized clinical studies. | Annagiulia Gramenzi Carmela Cursaro Marzia Margotti Clara Balsano Alessandra Spaziani Simona Anticoli Elisabetta Loggi Maddalena Salerno Silvia Galli Giuliano Furlini Mauro Bernardi Pietro Andreone | 2009 | World Journal of Gastroenterology2009，15，47： | 1 |
| 4 | Long Term Follow-up and Outcome of Liver Transplantation for Alcoholic Liver Disease: A Single Center Case-control Study 显示文摘 | Maurizio Biselli MD Annagiulia Gramenzi MD Massimo Del Gaudin MD | 2010 | J Clin Gastroenterol2010，44，1： | 1 |
| 5 | Long Term Follow-up and Outcome of Liver Transplantation for Alcoholic Liver Disease: A Single Center Case-control Study显示文摘 | Maurizio Biselli Annagiulia Gramenzi Massimo Del Gaudio Matteo Ravaioli Giovanni Vitale Stefano Gitto Gian Luca Grazi Antonio Daniele Pinna Pietro Andreone Mauro Bernardi | 2010 | Journal of Clinical Gastroenterology2010，，1： | 1 |
| 6 | Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver显示文摘 | Annagiulia Gramenzi Fabio Conti Calogero Cammà Antonio Grieco Antonino Picciotto Caterina Furlan Domenico Romagno Paolo Costa Maria Rendina Fausto Ancarani Maria Chiaramonte Gabriella Verucchi Antonio Craxì Mauro Bernardi Pietro Andreone | 2012 | Digestive and Liver Disease2012，，8： | 1 |
| 7 | Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival显示文摘 | Valentina Santi Franco Trevisani Annagiulia Gramenzi Alice Grignaschi Federica Mirici-Cappa Paolo Del Poggio Maria Anna Di Nolfo Luisa Benvegnù Fabio Farinati Marco Zoli Edoardo Giovanni Giannini Franco Borzio Eugenio Caturelli Maria Chiaramonte Mauro Ber | 2010 | Journal of Hepatology2010，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员